Koers Vertex Pharmaceuticals Incorporated
Aandelen
VRTX
US92532F1003
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
400,2 USD | -0,49% | +0,62% | -1,65% |
Omzet 2024 * | 10,72 mld. 9,98 mld. | Omzet 2025 * | 11,74 mld. 10,93 mld. | Marktkapitalisatie | 103 mld. 96,34 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 3,85 mld. 3,59 mld. | Nettowinst (verlies) 2025 * | 4,43 mld. 4,13 mld. | EV/omzet 2024 * | 8,08 x |
Nettoliquiditeiten 2024 * | 16,86 mld. 15,71 mld. | Nettoliquiditeiten 2025 * | 21,22 mld. 19,77 mld. | EV/omzet 2025 * | 7 x |
K/w-verhouding 2024 * |
26,9
x | K/w-verhouding 2025 * |
23,4
x | Werknemers | 5.400 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,89% |
Recentste transcriptie over Vertex Pharmaceuticals Incorporated
1 dag | -0,49% | ||
1 week | +0,62% | ||
Lopende maand | +1,87% | ||
1 maand | -2,26% | ||
3 maanden | -5,77% | ||
6 maanden | +6,27% | ||
Lopend jaar | -1,65% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 51 | 01-02-17 | |
Jeffrey Leiden
CHM | Chairman | 68 | 08-07-09 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 10-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 08-06-17 |
Jeffrey Leiden
CHM | Chairman | 68 | 08-07-09 |
Bruce Sachs
BRD | Director/Board Member | 64 | 01-01-98 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
7.67% | 0 M€ | 0,00% | - | |
7.08% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
02-05-24 | 400,2 | -0,49% | 1 051 248 |
01-05-24 | 402,1 | +2,38% | 1 256 483 |
30-04-24 | 392,8 | -0,86% | 1 727 934 |
29-04-24 | 396,2 | -0,32% | 604 570 |
26-04-24 | 397,5 | -0,06% | 682 467 |
uitgestelde koers Nasdaq, 02 mei 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,65% | 103 mld. | |
+6,75% | 101 mld. | |
+5,71% | 23,07 mld. | |
-12,60% | 22,23 mld. | |
-9,70% | 18,05 mld. | |
-39,98% | 17,18 mld. | |
-10,17% | 16,94 mld. | |
+6,12% | 14,07 mld. | |
+35,47% | 12,35 mld. | |
+307,09% | 8,35 mld. |